Search results
Added:
1 year ago
ESC HF 25 - TITRATE-HF shows 65% of patients with de novo heart failure receive guideline recommended medical therapy at 6 months in the Netherlands.Dr Jasper Brugts (Erasmus University Medical Centre, NL) joins us to discuss the outcomes from the TITRATE-HF study, which investigated adherence to the 2021 ESC guideline reccommendations for patients with heart failure with reduced ejecton fraction…
View more
Added:
1 year ago
ESC HF 25 - Outcomes from a study investigating liver stiffness measurement as a non-invasive method to assess central venous pressure showed immediate results at bedside obtained in >4 minutes, with the procedure easily performed by a trained nurse.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses a pilot validation study investigating liver stiffness as a non-invasive…
View more
Added:
2 weeks ago
HFA Congress 2026 — Dr Ida Arentz Taraldsen (Amager and Hvidovre Hospital, Copenhagen University Hospital, Hvidovre, DK) discusses REDOX-AHF, a prospective, randomised, blinded, multicentre pilot trial evaluating restrictive versus liberal oxygenation targets in patients hospitalised with acute heart failure and pulmonary congestion.Although oxygen therapy is widely used in the acute management…
View more
Added:
2 weeks ago
HFA Congress 2026 — Dr Nir Uriel (NewYork-Presbyterian, New York, US) discusses findings from a comparative analysis evaluating survival outcomes in middle-aged and older patients with advanced heart failure treated with left ventricular assist device (LVAD) therapy or heart transplantation.Drawing on two prospectively collected data sets: the Momentum 3 trial (HeartMate 3) and the UNOS…
View more
Added:
1 year ago
ESC HF 25 - Findings from a French nationwide cohort study investigating cardiologist follow-up show greater reduction in all-cause mortality associated with annual cardiology hospital visits.Dr Guillaume Baudry (University Hospital of Brabois, Nancy, FR) discusses findings from a nationwide trial investigating the prognostic value of heart failure stratification and cardiologist follow-up in…
View more
Added:
1 year ago
ESC HFA 25 - The WICD-MI study finds heart failure to be frequent in patients with persistent left ventricular dysfunction after acute myocardial infarction.We are joined onsite by Dr Mathieu Echivard (University Hospital of Nancy, Nancy, FR) to discuss key findings from a study investigating heart failure events in patients with persistent left ventricular dysfunction after acute myocardial…
View more
Added:
2 years ago
HFA 24 - We are joined onsite by Dr Michael Kiernan (Tufts University School of Medicine, US) to discuss the findings from the PROACTIVE-HF Trial.PROACTIVE-HF is a prospective, multicenter, open-label single arm trial which aimed to assess the device safety and efficacy of the Cordella Pulmonary Artery Sensor System in a population of 529 New-York Heart Association (NYHA) class III heart failure…
View more
Added:
2 years ago
HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial.RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure, who had…
View more
Added:
2 years ago
HFA 24 - We are joined by Dr Jasper J Brugts (Erasmus University Medical Centre, NL) to discuss the findings of a predefined subgroup analysis of the MONITOR-HF study (NTR7672).MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation,…
View more
Added:
1 year ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure…
View more